110.Jean-Luc Vachiéry, Ryan J. Tedford, Stephan Rosenkranz et al. Pulmonary hypertension due to left heart disease Eur Respir J. 2019 Jan 24; 53(1). pii: 1801897.
111.Borlaug BA, Nishimura RA, Sorajja P et al. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail 2010; 3:588–595.
112.Hager WD, Collins I, Tate JP et al. Exercise during cardiac catheterization distinguishes between pulmonary and left ventricular causes of dyspnea in systemic sclerosis patients. Clin Respir J 2013; 7: 227–236.
113.Maor E, Grossman Y, Balmor RG et al. Exercise haemodynamics may unmask the diagnosis of diastolic dysfunction among patients with pulmonary hypertension. Eur J Heart Fail. 2015; 17(2):151–158.
114.Hoeper MM, Maier R, Tongers J, Niedermeyer J, Hohlfeld JM, Hamm M, Fabel H. Determination of cardiac output by the Fick method, thermodilution, and acetylene rebreathing in pulmonary hypertension. Am J Respir Crit Care Med 1999; 160: 535–541.
115.Opitz CF, Blindt R, Blumberg F, Borst MM, Bruch L, Leuchte HH, Lichtblau M, Nagel C, Peters K, Rosenkranz S, Schranz D, Skowasch D, Tiede H, Weil J, Ewert R. Pulmonary hypertension: Hemodynamic evaluation. Updated Recommendations of the Cologne Consensus Conference 2011. Int J Cardiol. 2011 Dec; 154 Suppl 1:S13-9.
116.Grünig, E., Benjamin, N., Krüger, U., Kaemmerer, H., Harutyunova, S., Olsson, K. M., Klose, H. General measures and supportive therapy for pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018 // International Journal of Cardiology. 2018. doi:10.1016/j.ijcard.2018.08.085.
117.Hoeper MM, Olschewski H, Ghofrani HA, Wilkens H, Winkler J, Borst MM, Niedermeyer J, Fabel H, Seeger W. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J Am Coll Cardiol 2000; 35(1):176–182.
118.Eyries M, Montani D, Girerd B et al. EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nat Genet 2014; 46:65–69.
119.Benza RL, Gomberg-Maitland M, Miller DP, Frost A, Frantz RP, Foreman AJ, Badesch DB, McGoon MD. The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest. 2012; 141(2):354–362.
120.Escribano-Subias P, Blanco I, López-Meseguer M, Lopez-Guarch CJ, Roman A, Morales P, Castillo-Palma MJ, Segovia J, Gómez-Sanchez MA, Barberà JA; REHAP investigators. Survival in pulmonary hypertension in Spain: insights from the Spanish registry. Eur. Respir. J. 2012; 40(3): 596–603.
126
121.Lee WT, Ling Y, Sheares KK, Pepke-Zaba J, Peacock AJ, Johnson MK. Predicting survival in pulmonary arterial hypertension in the UK. Eur. Respir. J. 2012; 40(3): 604– 611.
122.Medrek SK, Sahay S. Ethnicity in pulmonary arterial hypertension: possibilities for novel phenotypes in the age of personalized medicine. Chest 2018; 153(2):310–320.
123.Talwar A, Sahni S, Talwar A, Kohn N, Klinger JR. Socioeconomic status affects pulmonary hypertension disease severity at time of first evaluation. Pulm Circ. 2016; 6(2):191–195.
124.Wu WH, Yang L, Peng FH, et al. Lower socioeconomic status is associated with worse outcomes in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2013; 187(3):303–310.
125.Launay D, Sitbon O, Hachulla E, Mouthon L, Gressin V, Rottat L, Clerson P, Cordier JF, Simonneau G, Humbert M. Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. Ann Rheum Dis. 2013; 72(12):1940–1946.
126.Poms AD, Turner M, Farber HW, Meltzer LA, McGoon MD. Comorbid conditions and outcomes in patients with pulmonary arterial hypertension: a REVEAL registry analysis. Chest. 2013; 144(1): 169–176.
127.Savarese G., Paolillo S., Costanzo P., D'Amore C., Cecere M., Losco T., Musella F., Gargiulo P., Marciano C., Perrone-Filardi P. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials // J. Am. Coll. Cardiol. – 2012. – Vol. 60. – N. 13. – P. 1192–1201.
128.Казымлы А. В., Березина А. В., Рыжков А. В., Козленок А. В., Наймушин А. В., Моисеева О. М. Кардиопульмональное тестирование как метод оценки степени тяжести пациентов с прекапиллярной легочной гипертензией // Кардиология. –
2014. – Т. 54. – № 12. – С. 22–28.
129.Kylhammar D, Kjellström B, Hjalmarsson C, et al. A comprehensive risk stratification at
early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart
J 2018; 39: 4175–4181.
130.Hoeper MM, Kramer T, Pan Z, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J 2017; 50: 1700740.
131.Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J 2017; 50: 1700889.
127
132. Hoeper M, Pittrow D, Opitz C, et al. Risk assessment in pulmonary arterial
hypertension. Eur Respir J 2018; 51: 1702606.
133.Löwe B, Gräfe K, Ufer C, et al. Anxiety and depression in patients with pulmonary hypertension. Psychosom Med 2004; 66:831-6.
134.Алехин А. Н., Андреева Е. В., Трифонова Е. А., Гончарова Н. С., Моисеева О. М.
Социальная и психологическая адаптация пациентов с синдромом Эйзенменгера.
Научные заметки института Лесгафта 2012; 91(9): 14–22.
135.Morris N.R., Kermeen F.D., Holland A.E. Exercise-based rehabilitation programmes for pulmonary hypertension. //Cochrane Database of Systematic Reviews. 2017. doi:10.1002/14651858.cd011285.pub2.
136.Chia K. S. W., Wong P. K. K., Faux S. G. et al. The benefit of exercise training in pulmonary hypertension: a clinical review. Internal Medicine Journal 2017; 47(4), 361– 369. doi:10.1111/imj.13159.
137.Ehlken N., Lichtblau1 M., Klose H., Weidenhammer J., Grünig E. et al. Exercise training improves peak oxygen consumption and haemodynamics in patients with severe pulmonary arterial hypertension and inoperable chronic thrombo-embolic pulmonary hypertension: a prospective, randomized, controlled trial. Eur heart J.; 37(1): 35-44. doi: 10.1093/eurheartj/ehv337.
138.Yuan P., Yuan X.T., Sun X.Y., Pudasaini B., Liu J.M., Hu Q.H. Exercise training for pulmonary hypertension: A systematic review and meta-analysis. //International journal of cardiology. 2014; 178:142–146.
139.Pandey A., Garg S., Khunger M., Garg S., Kumbhani D.J., Chin K.M. et al. Efficacy and Safety of Exercise Training in Chronic Pulmonary Hypertension: Systematic Review and Meta-Analysis. // Circulation Heart failure. 2015; 8:1032–1043.
140.Buys R., Avila A., Cornelissen V.A. Exercise training improves physical fitness in patients with pulmonary arterial hypertension: a systematic review and meta-analysis of controlled trials. BMC Pulm Med. 2015; 15:40.
141.Steppan J., Diaz-rodriguez N., Barodka V. M., et al. Focused Review of Perioperative Care of Patients with Pulmonary Hypertension and Proposal of a Perioperative Pathway. Cureus 2018 10(1): e2072. DOI 10.7759/cureus.2072.
142.Thangamathesvaran, L., Armenia, S. J., Merchant, A. M. The effect of pulmonary hypertension on inpatient outcomes of laparoscopic procedures. // Updates in Surgery. 2018 doi:10.1007/s13304-018-0556-y.
128
143.Pilkington S. A., Taboada D., Martinez G. Pulmonary hypertension and its management in patients undergoing non-cardiac surgery//Anaesthesia 2015, 70, 56–70.
144.Sarkar MS, Desai PM. Pulmonary hypertension and cardiac anesthesia: Anesthesiologist's perspective. Ann Card Anaesth 2018; 21:116–22.
145.Díaz-Gómez J.L., Ripoll J.G., Mira-Avendano I. Multidisciplinary Perioperative Management of Pulmonary Arterial Hypertension in Patients Undergoing Noncardiac Surgery. Southern medical journal 2018. Vol.111 (11) DOI: 10.14423/SMJ.0000000000000755.
146.Легочная гипертензия. Под редакцией С. Н. Авдеева. Москва. ГЭОТАР-Медиа. 2019.
– 608 с.
147.Klinger J R., Elliott G, Levine D J., Bossone E, Duvall L, Fagan K, Frantsve-Hawley J, Kawut SM., Ryan J J., Rosenzweig EB., Sederstrom N, Steen VD., Badesch DB. Therapy for Pulmonary Arterial Hypertension in Adults Update of the CHEST Guideline and Expert Panel Report CHEST 2019; 155(3):565–586.
148.Fuster V., Steele P.M., Edwards W.D., Gersh B.J. et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation. 1984; 70:580–587.
149.Bjornsson J., Edwards W.D. Primary pulmonary hypertension: a histopathologic study of 80 cases. Mayo Clin Proc. 1985; 60:16–25.
150.Preston IR, Roberts KE, Miller DP, Sen GP, Selej M, Benton WW et al. Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL). Circulation. 2015; 132(25):2403–2411.
151.Ngian GS, Stevens W, Prior D, Gabbay E, Roddy J, Tran A et al. Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study. Arthritis Res Ther.2012; 14(5): R213.
152.Olsson K.M., Delcroix M., Ghofrani H.A., Klose H., Claussen M., Ewert R., Opitz C.F., Vizza C.D., Scelsi L., Vonk-Noordegraaf A., Kaemmerer H., Gibbs J.S., Coghlan G., Pepke-Zaba J., Schulz U., Gorenflo M., Pittrow D., Hoeper M.M. Anticoagulation and survival in pulmonary arterial hypertension: results from the comparative, prospective registry of newly initiated therapies for pulmonary hypertension (COMPERA). Circulation.2014; 129:57–65.
153.Said K. Anticoagulation in pulmonary arterial hypertension: Contemporary data from COMPERA registry. Glob Cardiol Sci Pract 2014; 2014(2): 48–52.
129
154.Roldan T, Rios JJ, Villamanan E, Waxman AB. Complications associated with the use of oral anticoagulation in patients with pulmonary arterial hypertension from two referral centers. Pulm Circ. 2017; 7(3):692–701.
155.Sandoval J, Santos LE, Córdova J, Pulido T, Gutiérrez G, Bautista E et al. Does anticoagulation in Eisenmenger syndrome impact long-term survival? Congenit Heart Dis. 2012; 7(3):268–276. doi:10.1111/j.1747-0803.2012.00633.x.
156.Гончарова Н. С., Симакова М. А., Моисеева О. М. Антитромботическая терапия у пациентов с легочной артериальной гипертензией. Артериальная гипертензия. 2019;
25(1):25–33.
157.Ammash N, Warnes CA. Cerebrovascular events in adult patients with cyanotic congenital heart disease. J Am Coll Cardiol. 1996; 28(3):768–772.
158.Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P; ESC Scientific Document Group. 2016 ESC Guidelines for the
management of atrial fibrillation developed in collaboration with EACTS. Eur Heart
J. 2016; 37(38):2893–2962.
159.Jentzer, J. C., Mathier, M. A. Pulmonary Hypertension in the Intensive Care Unit. Journal of Intensive Care Medicine. 2015 31(6), 369–385.
160.Condliffe R, Kiely DG Critical care management of pulmonary hypertension. BJA Education. 2017; 17(7): 228–234.
161. Rhodes CJ, Wharton J, Howard L, Gibbs JS, |
Vonk-Noordegraaf A, Wilkins |
MR. |
Iron deficiency in pulmonary arterial hypertension: |
a potential therapeutic target. |
Eur |
Respir J. 2011; 38(6):1453–1460. |
|
|
162.Rajdev A., Garan H., Biviano A. Arrhythmias in Pulmonary Arterial Hypertension// Prog Cardiovasc Dis. 2012; 55(2): doi:10.1016/j.pcad.2012.06.002.
163.Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327(2):76–81.
164.Olschewski H. Inhaled iloprost for the treatment of pulmonary hypertension // Eur. Respir. Rev. – 2009. – Vol. 18. – N. 111. – P. 29–34.
165.Opitz CF, Wensel R, Winkler J, et al. Clinical efficacy and survival with first-line inhaled
iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart
J 2005; 26: 1895–1902.
166.Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006; 28: 691–694.
130